General Notices

• Change to NIDCD Administrative Reduction Guidance for Modular R01 Awards
  (NOT-DC-21-005)
  National Institute on Deafness and Other Communication Disorders
  

• Notice to Rescind NOT-EB-21-018 Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
  (NOT-EB-21-027)
  National Institute of Biomedical Imaging and Bioengineering
  

• Autism Centers of Excellence (ACE) Funding Opportunity Announcements: Frequently Asked Questions
  (NOT-HD-21-045)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  

Notice of Changes to Funding Opportunities

• Notice of Correction to Salary information in PAR-21-295, NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)
  (NOT-CA-21-116)
  National Cancer Institute
  

• Notice of Correction to PAR-21-166 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"
  (NOT-CA-21-119)
  National Cancer Institute
  

• Notice of Early Termination of RFA-CA-21-057, "A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Not Allowed)"
  (NOT-CA-21-120)
  National Cancer Institute
  

• Notice of NIDA's Participation in PA-20-144, "Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)"
  (NOT-DA-21-075)
  National Institute on Drug Abuse
  

• Notice of NIDA's Participation in PA-20-145, "Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)"
  (NOT-DA-21-076)
  National Institute on Drug Abuse
  

• Notice of Early Expiration of PAR-21-022, "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)"
  (NOT-DA-21-077)
  National Institute on Drug Abuse
  

• Notice of Early Expiration of PAR-21-023, "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)"
  (NOT-DA-21-078)
  National Institute on Drug Abuse
  

• Notice of clarification in RFA-DA-22-022, " Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional)"
  (NOT-DA-21-083)
  National Institute on Drug Abuse
  

• Notice of Change to Award Information and Application and Submission Instructions for RFA-DK-21-019, National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional)
  (NOT-DK-21-027)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Research Strategy Section Page Limits for RFA-DK-21-502, Limited Competition for the Data Coordinating Center (DCC) for the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U24 Clinical Trial Optional)
  (NOT-DK-21-028)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Extension of Application Due Date and Funding Opportunity Announcement (FOA) Identified under Announcement Type for RFA-DK-20-028, Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed)
  (NOT-DK-21-029)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Key Dates of RFA-MH-21-175, "BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)"
  (NOT-MH-21-345)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  

• Notice of Change to NOT-NS-20-038 "Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)"
  (NOT-NS-22-027)
  National Institute of Neurological Disorders and Stroke
  

Funding Opportunities

• Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
  (PAR-21-329)
  National Cancer Institute
  Application Receipt Date(s): November 05, 2024
  
  

• NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)
  (PAR-21-333)
  National Cancer Institute
  Application Receipt Date(s): November 4, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
  (PAR-21-337)
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 13, 2024
  
  

• Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
  (PAR-21-338)
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): September 13, 2024
  
  

• Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
  (PAR-22-035)
  National Institute of Mental Health
  Application Receipt Date(s): January 07, 2025
  
  

• Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
  (PAR-22-036)
  National Institute of Mental Health
  Application Receipt Date(s): January 07, 2025
  
  

• Limited Competition:Caenorhabditis Intervention Testing Program Data Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-AG-22-028)
  National Institute on Aging
  Application Receipt Date(s): October 27, 2021
  
  

• Limited Competition: Renewal of the Caenorhabditis Intervention Testing Program (U01 Clinical Trial Not Allowed)
  (RFA-AG-22-029)
  National Institute on Aging
  Application Receipt Date(s): October 27, 2021
  
  

• SUNBEAM - Analysis and Bioinformatics Center (ABC) (UM1 Clinical Trial Not Allowed)
  (RFA-AI-21-060)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): February 15, 2022
  
  

• Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-068)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): February 09, 2022
  
  

• The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
  (RFA-CA-21-059)
  National Cancer Institute
  Application Receipt Date(s): November 18, 2021
  
  

• Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Optional
  (RFA-FD-22-003)
  Food and Drug Administration
  Application Receipt Date(s): November 29, 2021